BNTX: Rega marang dodolan BioNTech Inc.
BioNTech SE (BNTX) attracts leading immunologists through large-scale scientific investments and ambitious goals. The price-to-sales ratio confirms this strategy, where the value 7.50 reflects the current metric. Leadership is driven by a flexible mRNA platform for combating cancer and viruses, while supply reliability is guaranteed by streamlined cold-chain logistics.
Rincian metrik lan analitis perusahaan BioNTech Group (BNTX)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal BioNTech SE|BNTX - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal BioNTech Pharma|BNTX - Gunggung utang perusahaan|Utang marang modal buku BioNTech Group|BNTX - Utang jangka dawa perusahaan|Utang jangka cendhak BioNTech|Indikator likuiditas cepet biontech.de
- rincian asil keuangan lan kelipatan valuasi:
BNTX - Bathi resik|Penghasilan resik sing dikarepake BioNTech SE|BNTX - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi BioNTech Inc.|BNTX - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan BioNTech Group|BNTX - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan BioNTech|BNTX - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan biontech.de|BNTX - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep BioNTech SE
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:biontech.de
The lack of a commercial drug portfolio and a dependence on costly R&D projects deprive BioNTech SE (BNTX) of the ability to influence market pricing. This capitalization-to-revenue ratio measures the premium over current sales, allowing investors to assess the risk of overpaying for future expectations; meanwhile, inflated metric values signal a potential correction in the asset's value in the absence of new growth drivers.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ABVX (Abivax S.A.)|ADMA Biologics Inc (ADMA) - Rega marang dodolan|Protagonist Therapeutics Inc - Multiplikator P/S|IMVT: Rasio rega marang pendapatan|KNSA: Multiplikator P/S|GRFS - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Adaptive Biotechnologies Corporation|Rega marang dodolan Celldex Therapeutics Inc CLDX|Rasio rega marang pendapatan Aurinia Pharma (AUPH)|BioCryst Corp - Rasio kapitalisasi marang pendapatan|Vera Therapeutics, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan DNTH (dianthustx.com)|Pharvaris - Multiplikator P/S|Rega marang dodolan AbCellera Biologics Inc.|TRML: Multiplikator P/S|Kapitalisasi marang pendapatan Precigen Corp|PHAR (Pharming Group N.V.) - Multiplikator P/S|NKTR: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan UPB (Upstream Bio)|ZBIO (Zenas Bio) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Immunome Corp IMNM|Koefisien rega marang pendapatan Gossamer Bio Corp. (GOSS)|KalVista Pharmaceuticals - Multiplikator P/S|Rega marang dodolan septerna.com|PVLA: Multiplikator P/S|SVRA (Savara Inc) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Rigel Pharmaceuticals Inc|Rasio kapitalisasi marang pendapatan ANAB (AnaptysBio Inc.)|Kapitalisasi marang pendapatan ATXS (Astria Therapeutics)|Kapitalisasi marang volume dodolan ENGN|RAPT Therapeutics - Kapitalisasi marang pendapatan|JBIO: Rasio kapitalisasi marang pendapatan|ACRS - Rasio rega marang pendapatan|Rasio rega marang dodolan KYTX|TLSA: Multiplikator P/S|cabalettabio.com - Rasio kapitalisasi pasar marang pendapatan|VTYX (Ventyx Biosciences, Inc.) - Multiplikator P/S|Multiplikator P/S Theratechnologies, Inc.|Rasio rega marang pendapatan Avalo Therapeutics Inc. (AVTX)|ELDN (Eledon Pharmaceuticals, Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Agenus AGEN|CLYM - Kapitalisasi marang pendapatan|Zura Bio - Multiplikator P/S|ATYR - Multiplikator P/S|ADAG (adagene.com) - Kapitalisasi marang pendapatan|Ikena Oncology - Rasio kapitalisasi pasar marang pendapatan|STTK (Shattuck Labs Inc) - Multiplikator P/S|Equillium Bio (EQ) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Connect Biopharma (CNTB)|Kapitalisasi marang pendapatan immunic-therapeutics.com IMUX|Rasio rega marang pendapatan Atara Bio ATRA|IFRX - Kapitalisasi marang pendapatan|XFOR: Kapitalisasi marang pendapatan|ACET - Multiplikator P/S|celularity.com (CELU) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan INMB|BRNS (Barinthus Bio) - Multiplikator P/S|Rega marang dodolan Kezar Life Sciences Inc KZR|Multiplikator P/S SABS|Rasio rega marang pendapatan AKTX (akaritx.com)|Multiplikator P/S ENLV (Enlivex Therapeutics Ltd.)|Koefisien rega marang pendapatan Q32 Bio Inc (QTTB)|GOVX - Rasio rega marang pendapatan|Rega marang dodolan Edesa Biotech Corp|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CARM|Kapitalisasi marang pendapatan XTLB|BOLT (Bolt Bio) - Kapitalisasi marang volume dodolan|Multiplikator P/S HCWB|APVO - Rega marang dodolan|Multiplikator P/S AIM (AIM ImmunoTech Inc.)|ADTX - Kapitalisasi marang pendapatan|GRI Bio - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan XRTX (XORTX Therapeutics Inc)|HIND (ReShape Lifesciences) - Kapitalisasi marang pendapatan|Revelation Biosciences Corp - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Indaptus Therapeutics|scinai.com (SCNI) - Koefisien rega marang pendapatan|Multiplikator P/S CALI|AFMD - Rega marang dodolan|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. - Rasio rega marang pendapatan|IGMS - Rasio rega marang pendapatan|ITOS (iteostherapeutics.com) - Rasio kapitalisasi marang pendapatan|OCEA (Ocean Biomedical) - Kapitalisasi marang pendapatan|TCBP: Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan THRD
